- Home /
- Events and Seminars /
- Seminars /
- The potential for Adjuvant Systems: Recent advances to tailor vaccine design
The potential for Adjuvant Systems: Recent advances to tailor vaccine design
10 Mar 2010
Wednesday 10 March 2010
Speakers: Dr Nathalie Garçon, VP, Head of Global Adjuvant Center for Vaccine Development GSK Biologicals and Dr. Marcelle Van Mechelen. Director of Immunology Research for GSK Biologicals
Venue: Bio21 Institute Auditorium, 30 Flemington Road, Parkville
Time: 1.00 to 2.00pm
No RSVP. All welcome.
Enquiries: Scott Preiss mailto:scott.s.preiss@gsk.com
Dr Nathalie Garçon Bio: After receiving her Pharm.D degree in 1982 and PhD (immunotoxicology, immunopharmacology) in 1985, Dr. Garçon spent 1 year in England as a postdoctoral research fellow (liposomes in vaccines) at the Royal free Hospital in London. She then spent 4 years in the United States (Baylor College of Medicine, Houston Texas, USA) first as postdoctoral research fellow, then as assistant professor, working on vaccine delivery systems and immunopotentiators. Dr Garçon joined SmithKline Beecham Biologicals -now GlaxoSmithKline- in 1990 where she set up the vaccine adjuvant and formulation group. She now is vice president, head of research and north America R&D; Her responsibilities encompasse basic immunology, formulation design and characterization, toxicology evaluation, research and clinical testing of human cell mediated immunity, biotechnologies (bioExperimentation, bio statistics, bio informatique). Expertise covers vaccinology from research to manufacturing, in particular immunology and immunological read-outs, formulation technology, analytical methods, animal experimentation and toxicology evaluation and testing.
